03.11.2020 06:59:50
|
Press Release: Addex Reports Q3 2020 Financial -2-
Company's clinical candidate selection, clinical trials and the
reporting of data therefrom. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to
known and unknown risks, uncertainties, and other factors, some of which
are beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including delays resulting
from the COVID-19 pandemic and healthcare regulatory considerations. The
Company cautions securityholders and prospective securityholders not to
place undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company will
not undertake any obligation to release publicly any revisions or
updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.
(END) Dow Jones Newswires
November 03, 2020 01:00 ET (06:00 GMT)

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Addex Therapeutics Ltd (spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Addex Therapeutics Ltd (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Addex Therapeutics Ltd. | 1,37 | -17,96% |
|